Evolution of the Average Target: Stem, Inc.

Evolution of the Target Price: Stem, Inc.

Changes in Analyst Recommendations: Stem, Inc.

a535d6459643102eccdecf6cb898485.ni_hR79i1fJzEDlnwWovu552buYWJ7pBtStJGPjItfo.-h2MA-AlhLkVI2sspBB90vYABtNzdu444nssWZP5xrjOG9Eh8QiNsBJ1AQ~6e286661b32d91108e5679501d835242
05-11 UBS Cuts Price Target on Stem to $10.50 From $12, Maintains Neutral Rating MT
03-10 UBS Adjusts Price Target on Stem to $12 From $18, Maintains Neutral Rating MT
25-10-31 UBS Adjusts Price Target on Stem Inc to $18 From $16, Maintains Neutral Rating MT
25-08-22 UBS Adjusts Stem Price Target to $16 From $8.60, Maintains Neutral Rating MT
25-04-14 UBS Downgrades Stem to Neutral From Buy, Cuts Price Target to $0.40 From $0.65 MT
25-03-07 UBS Adjusts Stem Price Target to $0.65 From $0.60, Maintains Buy Rating MT
24-11-08 UBS Trims Price Target on Stem to $0.60 From $1, Maintains Buy Rating MT
24-08-09 Susquehanna Downgrades Stem to Neutral From Positive, Adjusts Price Target to $0.50 From $2 MT
24-08-08 UBS Adjusts Price Target on Stem to $1 From $2.50, Maintains Buy Rating MT
24-08-07 TD Cowen Downgrades Stem to Hold From Buy, Adjusts PT to $1 From $4 MT
24-07-15 Susquehanna Trims Price Target on Stem to $2 From $2.50, Maintains Positive Rating MT
24-05-08 UBS Adjusts Price Target on Stem to $2.50 From $5, Maintains Buy Rating MT
24-04-11 Piper Sandler Trims Price Target on Stem to $2 From $3, Maintains Neutral Rating MT
24-03-22 Stem Shares Decline Following Downgrade From Goldman Sachs MT
24-03-22 Goldman Sachs Downgrades Stem to Neutral From Buy, Cuts Price Target to $2.50 From $5.50 MT
24-02-29 Susquehanna Trims Price Target on Stem to $4 From $5.50, Maintains Positive Rating MT
23-12-08 Morgan Stanley Cuts Price Target on Stem to $4 From $7, Maintains Equal-Weight Rating MT
23-11-03 Guggenheim Downgrades Stem to Neutral From Buy MT
23-11-01 Roth MKM Adjusts Price Target on Stem to $3.70 From $6, Maintains Neutral Rating MT
23-10-24 Barclays Trims Stem's Price Target to $5 From $6, Maintains Equalweight Rating MT
23-10-20 BNP Paribas Exane Initiates Stem With Neutral Rating, Price Target is $5 MT
23-10-17 Morgan Stanley Trims Price Target on STEM to $7 From $8, Keeps Equalweight Rating MT
23-10-17 Goldman Sachs Adjusts Price Target on Stem to $7 From $9.50, Maintains Buy Rating MT
23-10-06 Piper Sandler Trims Stem Price Target to $4 From $5, Maintains Neutral Rating MT
23-09-14 Goldman Sachs Trims Price Target on Stem to $9.50 From $11, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- +99.67%
+30.3%
+60.01%
+101.13%
+70.79%
+65.35%
+98%
- +34.4%
+27.33%
+68.67%
Average +65.57%
Weighted average by Cap. +41.73%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
6.010USD
Average target price
12.00USD
Spread / Average Target
+99.67%
High Price Target
18.00USD
Spread / Highest target
+199.50%
Low Price Target
7.500USD
Spread / Lowest Target
+24.79%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Piper Sandler
Goldman Sachs
Susquehanna
Morgan Stanley
Guggenheim
Roth MKM
Barclays
BNP Paribas Exane
Evercore ISI
Janney Capital
Wolfe Research
BofA Securities
Credit Suisse
Cowen
Northland Securities
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
6.010USD
Average target price
12.00USD
Spread / Average Target
+99.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STEM Stock
  4. Consensus Stem, Inc.